发布求助
文献互助 智能选刊 最新文献

European urology最新文献

筛选
英文 中文
Re: Aldo Brassetti, Gabriele Tuderti, Umberto Anceschi, et al. Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.019. 回复：Aldo Brassetti， Gabriele Tuderti， Umberto Anceschi等。无缝合线纯无钳机器人部分肾切除术：来自随机对照非劣效性试验的证据。Urol欧元。在出版社。http://dx.doi.org/10.1016/j.eururo.2026.04.019。
IF 25.2
European urology Pub Date : 2026-06-20 DOI: 10.1016/j.eururo.2026.06.007
Gianluca Giannarini, Antonio Amodeo, Angelo Porreca, Alessandro Crestani
{"title":"Re: Aldo Brassetti, Gabriele Tuderti, Umberto Anceschi, et al. Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.019.","authors":"Gianluca Giannarini, Antonio Amodeo, Angelo Porreca, Alessandro Crestani","doi":"10.1016/j.eururo.2026.06.007","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.06.007","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148298031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. 经皮雌二醇贴剂治疗局部晚期前列腺癌。
IF 25.2
European urology Pub Date : 2026-06-17 DOI: 10.1016/j.eururo.2026.05.019
Ian D Davis
{"title":"Re: Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.","authors":"Ian D Davis","doi":"10.1016/j.eururo.2026.05.019","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.019","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study. 新佐剂Sacituzumab Govitecan + Pembrolizumab，再加上Pembrolizumab，用于肌肉浸润性膀胱癌患者（SURE-02）：单组2期研究
IF 25.2
European urology Pub Date : 2026-06-17 DOI: 10.1016/j.eururo.2026.05.022
Laura S Mertens, Jan-Jaap J Mellema, Srikala Sridhar, Michiel S van der Heijden
{"title":"Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.","authors":"Laura S Mertens, Jan-Jaap J Mellema, Srikala Sridhar, Michiel S van der Heijden","doi":"10.1016/j.eururo.2026.05.022","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.022","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer. 膀胱切除术仍然是肌肉浸润性膀胱癌患者新辅助治疗后的标准治疗方法。
IF 25.2
European urology Pub Date : 2026-06-17 DOI: 10.1016/j.eururo.2026.05.009
Michael F Basin, Siamak Daneshmand
{"title":"Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer.","authors":"Michael F Basin, Siamak Daneshmand","doi":"10.1016/j.eururo.2026.05.009","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.009","url":null,"abstract":"<p><p>Radical cystectomy remains the standard of care after neoadjuvant therapy for muscle-invasive bladder cancer. While newer regimens (NIAGRA, KEYNOTE-B15/905) achieve impressive pathological complete response rates, the survival benefits from these trials were built on consolidative surgery, with a 88% cystectomy rate bladder preservation. Clinical complete response agrees with true pathological complete response only about half the time, meaning current restaging tools cannot reliably identify who is truly disease-free. Bladder preservation trials using systemic therapy alone (RETAIN-1/2, HCRN GU 16-257) have shown concerning rates of recurrence and metastasis even with biomarker selection. Trimodal approaches incorporating radiation (IMMUNOPRESERVE, INDIBLADE) are promising but remain early-phase. Until validated biomarkers and prospective trials prove otherwise, cystectomy should remain part of the curative-intent treatment paradigm.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Standardizing Time-to-Event Reporting in Single-arm BCG-unresponsive Registration Trials: A Case for Kaplan-Meier. 回复：单臂bcg无反应注册试验中标准化事件时间报告：Kaplan-Meier案例。
IF 25.2
European urology Pub Date : 2026-06-17 DOI: 10.1016/j.eururo.2026.05.018
David Zekan, Andres Correa
{"title":"Re: Standardizing Time-to-Event Reporting in Single-arm BCG-unresponsive Registration Trials: A Case for Kaplan-Meier.","authors":"David Zekan, Andres Correa","doi":"10.1016/j.eururo.2026.05.018","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.018","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Reliability of Urological Telesurgery Compared with Local Surgery: Multicentre randomised controlled trial. 泌尿外科远程手术与局部手术的可靠性比较：多中心随机对照试验。
IF 25.2
European urology Pub Date : 2026-06-17 DOI: 10.1016/j.eururo.2026.05.017
Prokar Dasgupta
{"title":"Re: Reliability of Urological Telesurgery Compared with Local Surgery: Multicentre randomised controlled trial.","authors":"Prokar Dasgupta","doi":"10.1016/j.eururo.2026.05.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.017","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial. 立体定向放射治疗雄激素抑制前列腺癌的低进展性疾病：TRAP试验的主要终点分析。
IF 25.2
European urology Pub Date : 2026-06-16 DOI: 10.1016/j.eururo.2026.05.023
Sekinat Yusuf, Aishah Azam, Inesh Sood, Hasan Al-Sattar, Vinod Mullassery, Sola Adeleke
{"title":"Re: Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.","authors":"Sekinat Yusuf, Aishah Azam, Inesh Sood, Hasan Al-Sattar, Vinod Mullassery, Sola Adeleke","doi":"10.1016/j.eururo.2026.05.023","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.023","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial. 关于：派姆单抗联合吉西他滨和同步低分割放疗作为膀胱保留治疗膀胱肌肉侵袭性尿路上皮癌：一项多中心2期试验。
IF 25.2
European urology Pub Date : 2026-06-16 DOI: 10.1016/j.eururo.2026.05.025
Hongzhi Ma, Qionghui Zhou
{"title":"Re: Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.","authors":"Hongzhi Ma, Qionghui Zhou","doi":"10.1016/j.eururo.2026.05.025","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.025","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer. 多学科方法预防和治疗前列腺癌放疗后晚期泌尿生殖系统不良事件。
IF 25.2
European urology Pub Date : 2026-06-06 DOI: 10.1016/j.eururo.2026.05.008
Amar U Kishan, Giulio Francolini, Declan G Murphy, Renu S Eapen, Paul Sargos, Giulia Marvaso, Piet Ost, Neha Vapiwala
{"title":"A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer.","authors":"Amar U Kishan, Giulio Francolini, Declan G Murphy, Renu S Eapen, Paul Sargos, Giulia Marvaso, Piet Ost, Neha Vapiwala","doi":"10.1016/j.eururo.2026.05.008","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.05.008","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell Carcinoma. 通过富马酸水合酶缺乏筛查扩大贝伐单抗-厄洛替尼治疗乳头状形态转移性肾细胞癌的药物靶标途径分析。
IF 25.2
European urology Pub Date : 2026-05-13 DOI: 10.1016/j.eururo.2026.04.026
Javier de Nicolás-Hernández, Carlos Valdivia, Alicia Arenas, Miguel A Zaballos, Mercedes Robledo, Cristina Rodríguez-Antona
{"title":"Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell Carcinoma.","authors":"Javier de Nicolás-Hernández, Carlos Valdivia, Alicia Arenas, Miguel A Zaballos, Mercedes Robledo, Cristina Rodríguez-Antona","doi":"10.1016/j.eururo.2026.04.026","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.04.026","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书